Search | eNauka

Research outputs

Impact of treatment interruptions due to toxicity on out come of patients with early stage non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiotherapy (Hfx RT) [2002]

Jeremic, Branislav; Nikolic, Nebojsa; Dagovic, Aleksandar ; Aleksandrovic, Jasna; Dagovic, S; Miloradovic, O; Bosnjakovic, S

Clinical Research In Radiation Oncology Of Lung Cancer. Why We Fail(Ed)? [2008]

Jeremic, Branislav

Clinical pretreatment prognostic factors in patients with glioblastoma multiforme treated with combined modality approach [2002]

Jeremic, Branislav; Milicic, Biljana R; Grujicic, Danica M; Nikolic, Nebojsa; Dagovic, Aleksandar ; Aleksandrovic, Jasna; Dagovic, S; Miloradovic, O; Bosnjakovic, S

Radiotherapy and concurrent daily carboplatin/paclitaxel in stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II trial [2004]

Jeremic, Branislav; Milicic, Biljana R; Acimovic, Ljubisa; Milisavljevic, Slobodan S; Radosavljevic-Asic, Gordana D

LOCAL FAILURE IN BREAST-CONSERVING THERAPY WITH REGARD TO LOCALISATION AND DOSE OF RADIOTHERAPY [2010]

Cihoric, Nikola; Aebersold, DM; Trajkovic, Goran Z; Loessl, Kristina

INTENSITY MODULATED RADIOTHERAPY (IMRT) IN THE TREATMENT OF CERVICAL CANCER PATIENTS - OUR EXPERIENCE [2010]

Cihoric, Nikola; Trajkovic, Goran Z; Aebersold, DM; Loessl, Kristina

Radiation therapy alone and with concurrent low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC). Single-institution experience in 250 patients [2007]

Jeremic, Branislav; Milicic, Biljana R

Evolution of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC) - single institution experience in 600 patients [2009]

Jeremić, Branislav; Miličić, Biljana

Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer [2013]

Milanović, D.; Jeremić, Branislav ; Grosu, A.L.; Rücker, G.; Henke, M.

Radiation therapy alone and with concurrent low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC) - single-institution experience in 250 patients [2007]